Company news: Forest Labs

Share this article:
FDA approved Forest's Daliresp (roflumilast) for the treatment of severe chronic COPD in adults 18 and up. The daily pill is indicated for decreasing the frequency of flare-ups or worsening of symptoms including breathlessness, chronic cough and excessive phlegm associated with bronchitis. The first-in-class drug is not indicated for treatment of primary emphysema, another form of COPD.
Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.